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Efficacy of regorafenib in 
gastrointestinal stromal tumours (GISTs) 
— case report
ABSTRACT 
The systemic treatment of gastrointestinal stromal tumours (GIST) is based on targeted therapies such as imatinib, 
sunitinib, sorafenib, or regorafenib. One of the most important treatment options is the recruitment of patients into 
clinical trials, especially in the late stage of the disease. 
Herein we present a case of a 62-year-old woman with metastatic GIST. In 2008, after a gastrectomy, she was 
recruited to the EORTC 62024 clinical trial. She was randomly assigned to the observational arm of the study. In 
2009 due to non-resectable recurrence of the disease, imatinib therapy was started, and continued until 2014. Then, 
due to another progression of the disease, the dose of imatinib was doubled and finally replaced by sunitinib. The 
tolerance of imatinib was satisfactory whereas the sunitinib therapy required dose modification due to a grade 
CTC3 toxicity. In 2015, due to a further progression, she received sorafenib for 12 months, and subsequently 
re-treatment with imatinib combined with chemotherapy based on the doxorubicin and dacarbazine schedule 
(the response to therapy lasted four months). Considering the patient’s good performance status, regardless 
of the fifth line of treatment, she was started on regorafenib. After the first course, the patient reported a definite 
improvement of the general condition and good tolerance to the therapy. The main complications were  hand-foot 
syndrome and diarrhoea (grade CTC2). On regorafenib treatment, the patient achieved a partial response. 
In case of further progression the patient will be offered participation in a clinical trial.
In GIST patients, regorafenib monotherapy after previous progression on imatinib, sunitinib, and sorafenib is an 
effective and well-tolerated treatment leading to clinical and radiological response.
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Introduction
Gastrointestinal stromal tumours (GIST) are the 
most common mesenchymal neoplasms of the gas-
trointestinal tract. GISTs probably derive from the 
progenitors of the myenteric (‘pacemaker‘) interstitial 
cells of Cajal, which are responsible for the genera-
tion of the peristaltic wave of the intestines [1, 2]. The 
overexpression of the membrane KIT receptor may be 
detected by immunohistochemical methods (CD117) 
on the histopathological sections of the tumour. This 
method is the most important criterion in the micro-
scopic diagnostics of GIST [3]. The molecular tests 
performed in patients with GIST show the presence of 
mutations of KIT and PDGFRA genes, which encode 
the membrane receptors possessing tyrosine kinase 
activity [4, 5]. The majority of KIT gene mutations are 
placed in exon 11 (about 70%) and less frequently in 
exon 9 (6–8%). Mutations may also occur in exons 
13 and 17 of this gene. In the majority of GIST without 
any mutations of the KIT gene some mutations are 
detected in the PDGFRA gene. These mutations are 
located in two exons of the PDGFRA gene (mostly in 
18 and more rarely in 11). The KIT and PDGFRA gene 
mutations are mutually exclusive (i.e. they do not oc-
cur simultaneously in both genes) [6–8]. The clinical 
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presentation of GIST is variable. GIST may present as 
a small tumour, randomly detected by the endoscopic 
tests (in this case the clinical course is usually relatively 
benign), or as an import neoplastic mass or a metastatic 
tumour — located mostly in the abdominal cavity [9]. 
Surgical-resection is a first-line treatment for primary 
GIST. In patients with high-risk GISTs adjuvant use of 
a small molecule tyrosine kinase inhibitor — imatinib 
— decreases the risk of relapse of the disease. Adjuvant 
therapy should be continued for three years from the 
date of the radical surgery. In case of the unresectable 
relapse or dissemination of the disease, the first-line 
treatment consists of imatinib administration and 
consecutive lines of sunitinib, regorafenib, or sorafenib 
[10]. GIST patients should be diagnosed (with use of 
molecular methods) and receive a treatment plan in 
a reference centre. 
Case report
We present a case of a 62-year-old woman with GIST 
in her stomach, who underwent a radical partial gastrec-
tomy in 2008. At the time of diagnosis, no mutations in 
the KIT and PDGFRA gene were detected. Because the 
factors of a high risk of relapse were present [11], the 
patient was enrolled into the clinical study: EORTC 
62024 — ‘Imatinib Mesylate or Observation Only in 
Treating Patients Who Have Undergone Surgery for 
Localised Gastrointestinal Stromal Tumour’. She was 
randomised to the observational arm. Non-resectable 
disease relapse with metastases to the liver and ret-
roperitoneal space was diagnosed in 2009. Prospec-
tive clinical studies of the use of imatinib in patients 
with non-resectable or metastatic GIST showed that 
a complete response is achieved in 5–7% of patients, 
a partial response in 40% of patients, and stable disease 
in 36% of threated subjects. [12, 13]. Moreover, the 
resection rate of the residual changes increases during 
therapy with imatinib [14, 15]. Therefore, the patient 
was stared on imatinib 400 mg per day, which resulted 
in partial remission with subsequent long-lasting stabi-
lisation of the disease and very good tolerance to the 
therapy. Due to the important decrease of the neoplastic 
masses, the patient was qualified for a pancreatoduo-
denectomy. She did not give her consent for surgery. 
That is why the imatinib therapy was continued at the 
recommended dose until the occurrence of another 
progression of the disease in 2014. The estimated rate 
of the disease progression during the 2–3 years of 
the imatinib therapy reaches 40–50% [16, 17]. In this 
clinical situation, according to the recommendations 
of the Polish Association of Clinical Oncology and of 
the European Society of Medical Oncology, imatinib 
should be continued at the escalated dose of 800 mg 
per day [18, 19]. The double dose of imatinib resulted 
in this patient in a three-month-long clinical response. 
Subsequently, further progression was observed and 
the patient was switched to sunitinib. In 2014 (as well 
as nowadays) sunitinib malonate — a small molecule 
tyrosine kinase inhibitor — was the only drug registered 
for the second-line treatment of GIST patients, resistant 
or intolerant (very rare) to imatinib. Sunitinib targets 
multiple tyrosine kinases receptors (e.g. KIT, PDGFR), 
vascular-endothelial growth factor receptor (VEGFR), 
and FLT-3 receptor. Data from the literature show 
that a median time to progression in GIST patients 
treated with sunitinib equals 6–8 months [20, 21]. Ac-
cording to the product characteristics, therapy with 
sunitinib should be started from the dose of 50 mg per 
day according to the following schedule: four weeks of 
therapy followed by two weeks of no treatment. The 
tolerance of sunitinib therapy is usually worse than that 
of imatinib. That is why the patients had intermitted 
symptoms of toxicity in grade CTC2 and CTC3, such as: 
arterial hypertension, palmar-plantar erythrodysesthe-
sia, diarrhoea, or hypothyroidism, requiring modifica-
tion of the sunitinib dose. Finally, the sunitinib dose 
was reduced from 50 mg to 25 mg per day. Tiredness, 
neutropaenia, thrombocytopaenia, diarrhoea, nausea, 
mucositis, and some other, rarely occurring side ef-
fects may be observed during therapy with sunitinib. 
A clinical study proved that the occurrence of arterial 
hypertension is a predictive factor of the response to 
sunitinib [22]. An alternative schedule of a continuous 
dosing, i.e. 37.5 mg per day without any pause, becomes 
generally accepted and seems to be more justified due 
to better tolerance of treatment [23]. 
In July 2015, due to further progression of the dis-
ease, the patient was qualified to receive sorafenib. In 
studies involving small groups of patients resistant to 
previous therapy with imatinib and sunitinib or intoler-
ant to these drugs, use of sorafenib resulted in reaching 
a median PFS (progression-free survival) of 6.4 months 
(95% CI, 4.6–8.0) and a median OS (overall survival) 
of 13.5 months ( 95% CI, 10.0–21.0) [24, 25]. Therapy 
with sorafenib was well tolerated by our patient. There 
was no need to modify the dose of the drug. The patient 
continued therapy with sorafenib at dose of 800 mg 
per day until subsequent progression of the disease in 
June 2016.
Because there was no accessible clinical trial and 
the patient remained in a good performance status, 
therapy with imatinib was restarted in combination with 
chemotherapy as per schedule ADIC (doxorubicin and 
dacarbazine). The disease stabilisation lasted for four 
months. 
Further progression of the disease in Septem-
ber 2016 resulted in the use of regorafenib — the 
most recent oral drug registered in the treatment of 
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Figure 1. Radiologic evaluation: A — initial imaging; B — after 6 months of therapy; C — after 9 months of therapy
A B C
patients with GIST, who have failed to respond to 
therapy with imatinib and sunitinib. Regorafenib is 
a multi-kinase inhibitor that inhibits the activity of, 
among others, KIT, RET, RAF1, BRAF, and TIE2, 
receptors responsible for the regulation of the neo-
plastic angiogenesis (VEGFR1-3, TEK) or neoplastic 
stroma (PDGFR and FGFR). In the GIRD clinical 
study, the use of regorafenib after failure of imatinib 
and sunitinib therapy resulted in occurrence of partial 
responses and high probability of reaching perma-
nent stabilisation of the disease. The grade 3/4 CTC 
side effects include: arterial hypertension, diarrhoea 
and palmar-plantar erythrodysesthesia, impotence, 
changes of the voice timbre/hoarseness, and tiredness 
[26]. The patient gave her consent for the proposed 
treatment, which in Polish reimbursement rules was 
founded by the patient’s private financial means. 
A significant clinical improvement was observed 
after the first course of therapy. The main observed 
side effect was hand-foot syndrome and diarrhoea in 
maximal grade 2 CTC. The side effects were observed 
mostly in the third week of the therapy. A radiological 
evaluation of the response is shown in Figure 1. The 
patient continued on regorafenib for 10 months. She 
first achieved a partial response, followed by dis-
ease stabilisation.
Subsequent progression of the disease was diagnosed 
in May 2017. According to the clinical data from the 
GIRD study [27, 28], which suggested the validity of 
the continuation of regorafenib therapy in patients with 
radiological progression of the disease and confirmed 
clinical benefit, the patient continued the treatment 
for another three months. In July 2017 regorafenib was 
stopped due to further clinically important progression 
of the disease detected by the CT imaging of the abdo-
men and of the true pelvis. We plan to enrol this patient 
into a clinical trial. The presence of KIT gene mutation in 
exon 11 was detected by the mutation analysis of a new 
neoplastic tissue sample. 
Summary
In the presented case the efficacy of sequentially 
used tyrosine kinase, as well as the tolerance of each 
therapy, was shown. The results of therapy obtained 
in the Department of Soft Tissue/Bone Sarcoma and 
Melanoma in the Maria Sklodowska-Curie Institute 
— Oncological Centre in Warsaw are similar to the 
ones previously cited. The optimal sequence of using 
the individual drugs as well as combinations of targeted 
agents, in subsequent lines of therapy, requires further 
investigation. In the majority of cases even during 
progression on therapy with one tyrosine inhibitor, the 
GIST cells remain partially sensitive to another TKI.
It is crucial to refer GIST patients with disease pro-
gression and good performance status to clinical trials in-
volving new molecularly targeted agents in monotherapy 
or combined with immunotherapy. Based on the data 
from clinicaltrials.gov, there are some ongoing stud-
ies with use of ponatinib or DCC-2618.  In the case of 
presence of V842V mutation of the PDGFRA gene, the 
efficacy of crenolanib r Blu285 is being tested. There are 
also some ongoing studies evaluating the efficacy of im-
munotherapy, involving accessible anti PD-1/PDL-1 an-
tibodies such as nivolumab or pembrolizumab as well 
as the anti-CTLA4 antibody — ipilimumab, used in 
monotherapy or in combination [29].
Our patient was offered participation in a II phase 
clinical trial: ‘Basket Study of Entrectinib (RXDX-101) 
for the Treatment of Patients with Solid Tumours Har-
bouring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene 
Rearrangements (Fusions)’. The study includes testing 
the mutation profile. In patients harbouring the tested 
mutations the response rate to entrectinib equals about 
80%. The aforementioned data are from a I phase clinical 
study involving 119 patients among whom 25 had a positive 
result of testing for presence of TRK1, NTRK2, NTRK3, 
ROS1, or ALK gene mutations. Very good tolerance of 
treatment with entrectinib should also be mentioned.  
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